Our lead product

Eroxon® is a topically applied gel which utilises our proprietary technology, developed specifically for the treatment of ED.

Eroxon® is a highly differentiated product by addressing significant unmet needs in the ED market.

Click on the circle icons to view more information about each section.

Speed of action

Data from two Phase 3 studies demonstrated that Eroxon® helps men get an erection within 10 minutes. In contrast, 'on demand' oral treatments typically take 30 -60 minutes to act.

Enables spontaneity

Because Eroxon® is a fast-acting topical treatment 1, it has the potential to remove the need for planning of sex associated with oral PDE5i medications.

Supports intimacy and partner involvement

As evidenced during the clinical trials, Eroxon® topical application and speed of onset means it can form part of foreplay and support intimate sexual experience. The topical application also encourages partner involvement.

Efficacy and safety profile

Eroxon® was shown to be an effective treatment for ED throughout the study phase of the development process and demonstrated a significantly higher statistical improvement across all ED patient severities than before treatment, along with an excellent safety profile.

The efficacy of Eroxon® is remarkable and has been shown to deliver clinically meaningful benefits to most sufferers with erectile dysfunction in two Phase 3 studies  but with significantly lower adverse events than current first line therapy. With topical application, it will be of particular appeal to mild to moderate ED patients who want a fast onset of action. Lack of drug interactions with prescription products will enable the product to be used with other medications such as nitrates and other cardiovascular drugs.  As such the product will be of great interest to the medical community

Professor David Ralph

Consultant Urologist at University College London and past president of the European Society of Sexual Medicine

  1. FM57 internal clinical study report